Stopping prostate cancer progression might be possible
Cancer Prostate Cancer Abiraterone

Stopping prostate cancer progression might be possible

Flávia Oliveira Geraldes
Flávia Oliveira Geraldes

In 10 seconds? A new study shows that a different treatment schedule might prevent prostate cancer from spreading to other parts of the body (a process called metastasization).

What’s the change in treatment? The big change is when men with prostate cancer are given a drug called abiraterone. Currently, only patients whose cancer has spread (metastasized) to other parts of the body receive this drug. Men whose cancers haven’t spread beyond the original site yet – that is, with “locally advanced prostate cancer” – are offered surgery, radiotherapy, or hormonal therapy. This study, however, shows that giving abiraterone sooner (to men with locally advanced disease) can reduce the long-term risk of death from the disease by about a half.

Get unlimited access to our 3-min Digests and other premium features!

Choose your plan.

Sparrow Insiders

$0 (Limited Offer)
  • Receive our daily Digest in your inbox
  • Created & reviewed by real scientists
  • Preview 380+ Digests in our library
  • Upgrade for unlimited learning
  • Unsubscribe anytime
  • Subject to availability
Join our first 25k subscribers for free! Signup Progress Bar Subscribe now for free

Sparrow Unlimited

$19 / month
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now

Sparrow Unlimited

$99 / year
  • One easy payment - save 56%
  • Talk with our scientists and ask them anything
  • Access 380+ summaries anywhere, anytime
  • Listen to our premium podcast
  • Weekly newsletter of the top 5 scientific findings
  • Daily updates with new content
  • Support independent science publishing
  • No advertisement
  • Cancel anytime
Learn more Subscribe now